Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer.
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.
Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC
Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
Durvalumab Combo Prolongs DFS in High-Risk BCG-Naive NMIBC
Data from POTOMAC support durvalumab plus BCG and induction and maintenance therapy as a new treatment option in BCG-naive, high-risk NMIBC.
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.
Upfront MRI Staging Improves Bladder Cancer-Specific Survival
Using multiparametric MRI for initial staging, then cystoscopic biopsy, improves bladder cancer-specific survival compared with transurethral resection of bladder tumor staging.
Nivolumab Sustains DFS Benefits in Muscle-Invasive Urothelial Carcinoma
Updated results from CheckMate 274 support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial carcinoma.